Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. O'Malley DM, et al. Gynecol Oncol. 2020 May;157(2):379-385. doi: 10.1016/j.ygyno.2020.01.037. Epub 2020 Feb 18. Gynecol Oncol. 2020. PMID: 32081463 Clinical Trial.
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Martin AG, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. Concin N, et al. Radiother Oncol. 2021 Jan;154:327-353. doi: 10.1016/j.radonc.2020.11.018. Radiother Oncol. 2021. PMID: 33712263
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Krop IE, et al. Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526538 Clinical Trial.
External and internal ontogenetic changes in the first rib.
García-Martínez D, Gil OG, Cambra-Moo O, Canillas M, Rodríguez MA, Bastir M, Martín AG. García-Martínez D, et al. Am J Phys Anthropol. 2017 Dec;164(4):750-762. doi: 10.1002/ajpa.23313. Epub 2017 Sep 23. Am J Phys Anthropol. 2017. PMID: 28941270
Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic.
Nasser S, Fotopoulou C, Gültekin M, Dimitrova D, Bilir E, Inci G, Morice P, Mirza MR, Martin AG, Berek J, Sehouli J; Collaborating Groups: European Network for Gynaecological Oncology Trials (ENGOT), European Society for Gynaecological Oncology (ESGO), Gynecological Cancer Intergroup (GCIG), Pan-Arabian Research Society for Gynecological Oncology (PARSGO), North-East German Gynecological Oncology Society (NOGGO). Nasser S, et al. Arch Gynecol Obstet. 2024 Jun 5. doi: 10.1007/s00404-024-07511-4. Online ahead of print. Arch Gynecol Obstet. 2024. PMID: 38836928